Empagliflozin is a medicine used to treat type 2 diabetes, heart failure and chronic kidney disease. It works by helping the kidneys remove extra sugar and salt from the body through urine. It's taken as a pill once a day.
Every report comes from a Lived member, sent anonymously.
Have you tried Jardiance (Empagliflozin) for Type 2 Diabetes?
Empagliflozin, sold as Jardiance, is a once-daily prescription tablet that started as a type 2 diabetes medicine and is now used just as often to protect the heart and kidneys. In the US it is approved to lower blood sugar, alongside diet and exercise, in adults and children 10 and older with type 2 diabetes. It is also approved to reduce the risk of cardiovascular death in adults with type 2 diabetes who already have heart or blood vessel disease; to reduce cardiovascular death and hospital stays in adults with heart failure; and to slow the loss of kidney function, and lower the risk of kidney failure, cardiovascular death and hospitalization, in adults with chronic kidney disease that is at risk of getting worse. The heart failure and kidney uses do not require diabetes, and the heart failure trials included people whose heart pumps weakly as well as people whose pumping strength is normal but whose heart is stiff. Empagliflozin is not used to manage blood sugar in type 1 diabetes, because it raises the risk of a dangerous acid buildup called diabetic ketoacidosis. It is not expected to help kidney disease caused by polycystic kidney disease, or in people who recently needed high-dose steroids or intravenous immune-suppressing treatment for their kidneys. Empagliflozin is also one ingredient in several type 2 diabetes combination tablets: Synjardy and Synjardy XR (with metformin), Glyxambi (with linagliptin) and Trijardy XR (with both). These carry the cautions of their other ingredients too, such as the rare but serious lactic acidosis warning that comes with metformin.
The kidneys filter sugar (glucose) out of the blood all day and then reabsorb it, so it isn't lost in urine. A transporter called SGLT2 (sodium-glucose cotransporter 2) does most of that reabsorbing, and it carries sodium back along with the sugar. Empagliflozin blocks SGLT2, so more sugar leaves the body in urine, which lowers blood sugar. At the usual 10 mg dose, people with type 2 diabetes pass roughly 64 grams of sugar a day this way. Because sodium is released too, the body sheds some salt and water. That lowers the pressure inside the kidney's tiny filters and eases the workload on the heart, which helps explain why the drug protects the heart and kidneys even in people without diabetes, although the full explanation is still being studied. The sugar-lowering effect depends on how much blood the kidneys filter, so it weakens as kidney function declines, while the heart and kidney benefits were shown in people with considerably reduced kidney function.
Empagliflozin is taken once a day in the morning, with or without food. The usual dose is 10 mg. For heart failure, kidney disease and cardiovascular protection, 10 mg is the dose. For blood sugar control in type 2 diabetes, the prescriber may raise it to 25 mg if more effect is needed and 10 mg is well tolerated. Combination tablets have their own strengths and schedules, so follow the instructions for the specific product. Before starting, the prescriber checks kidney function with an eGFR (estimated glomerular filtration rate), a blood-test estimate of how well the kidneys filter, where lower numbers mean weaker function. Below an eGFR of 30, empagliflozin is not recommended just for blood sugar, because it lowers sugar too little at that point. The heart failure and kidney trials, by contrast, enrolled people with an eGFR as low as 20, though not people on dialysis. The prescriber also makes sure a person is not dehydrated before the first dose. If a dose is missed, take it when remembered, but do not double the next one. Surgery, or a procedure that requires fasting for a long time, needs planning: empagliflozin is usually stopped at least 3 days beforehand when possible, and restarted once a person is stable and eating and drinking normally again.
The most common side effects come from having extra sugar in the urine. Genital yeast infections are the most typical and can affect both women and men. In trials of adults with type 2 diabetes, about 5 to 6 in 100 women taking empagliflozin had one, compared with about 1 to 2 in 100 on placebo. Urinary tract infections are also somewhat more common, especially in people who have had them repeatedly. Many people urinate more often and feel thirstier. The extra fluid loss can lower blood pressure and cause dizziness or light-headedness, particularly when standing up. This is more likely in older adults, people with reduced kidney function and people taking diuretics (water pills). Drinking enough fluids helps, and dizziness or fainting is worth reporting to the prescriber. Less often, dehydration leads to a sudden drop in kidney function, occasionally serious enough to need hospital care. In trials, empagliflozin taken alone caused low blood sugar no more often than placebo in adults. The risk rises when it is combined with insulin or a sulfonylurea (an older type of diabetes pill that makes the pancreas release more insulin), so the dose of those medicines may need lowering. In children 10 and older, low blood sugar was more common on empagliflozin whether or not they used insulin.
The most serious risk is ketoacidosis, a buildup of acids in the blood that can be fatal. Unlike typical diabetic ketoacidosis, it can occur while blood sugar is normal or only mildly raised, so a normal glucose reading does not rule it out. It is more likely during an illness with fever, when eating very little or following a ketogenic diet, with heavy alcohol use, dehydration or surgery, after missed or reduced insulin doses, and in people with a past pancreatitis or pancreas surgery. Signs include nausea, vomiting, stomach pain, unusual tiredness and labored breathing. If they appear, stop empagliflozin and get emergency medical care right away, mentioning the medicine so that ketones are checked. The care team may also advise pausing it during a short illness when a person cannot eat or drink normally. Serious urinary infections, including kidney infections and infections that spread to the bloodstream, have occurred. A much rarer danger is Fournier's gangrene, a life-threatening tissue infection of the genitals and the area between the genitals and the rectum that needs urgent surgery. Seek medical care promptly, the same day, for pain, tenderness, redness or swelling in that area together with a fever above 100.4°F or feeling generally unwell. Across empagliflozin trials, lower leg and foot amputations were uncommon and only slightly more frequent than on placebo (about 5 versus 4 per 1,000 people each year), mostly toes and the middle of the foot in people with poor circulation or foot infections. Routine foot care matters, and new pain, sores, ulcers or infection on a leg or foot should be reported to the care team right away. Serious allergic reactions, including angioedema (deep swelling of the skin), can happen; stop the drug and contact the prescriber for hives or swelling, and get emergency help for swelling of the face, lips, tongue or throat, or trouble breathing. Diuretics add to fluid loss. Empagliflozin can lower blood levels of lithium, a mood stabilizer for bipolar disorder, so lithium levels are checked more often. Urine glucose tests will read positive and cannot be used to track diabetes. Based on animal studies showing effects on the developing kidney, empagliflozin is not recommended in the second and third trimesters of pregnancy or while breastfeeding; tell the prescriber as soon as possible about a pregnancy.
Empagliflozin starts raising sugar in the urine from the first dose. Its effect on diabetes is judged mainly with the A1C test, which reflects average blood sugar over the past three months, so it takes a few months to see the full result. More frequent urination is common early on, and kidney blood tests may shift slightly after starting, which the care team watches with periodic checks. For heart failure and kidney disease, the benefit is not something a person feels from day to day. It shows up as fewer hospital stays and slower kidney decline over years. In the main trial in people whose heart pumps weakly, about 19 in 100 people taking it died of cardiovascular causes or were hospitalized for heart failure over about 16 months, compared with about 25 in 100 on placebo. In chronic kidney disease, about 13 in 100 had their kidney disease progress or died of cardiovascular causes over two years, compared with about 17 in 100 on placebo. Empagliflozin is usually continued long term as part of ongoing diabetes, heart or kidney care. The prescriber reviews it as kidney function, other medicines and overall health change, rather than stopping it once things feel stable.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Jardiance (Empagliflozin), what you've noticed, or ask the community a question.